Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project.

Paolicelli D, Borriello G, Clerici R, Colombo E, Croce D, D'Amico E, De Rossi N, Di Sapio A, Fenu G, Maimone D, Marfia GA, Moccia M, Perini P, Piscaglia MG, Razzolini L, Riccaboni M, Signoriello E, Agostoni G, Farina A, Mondino M, Berruto F, Tettamanti A, Donnaloja F, Tortorella C

Open source

DOI: 10.1007/s40120-024-00644-3
Published: 2024 Oct
Container: Neurology and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40120-024-00644-3,
  title = {Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project.},
  author = {Paolicelli D and Borriello G and Clerici R and Colombo E and Croce D and D'Amico E and De Rossi N and Di Sapio A and Fenu G and Maimone D and Marfia GA and Moccia M and Perini P and Piscaglia MG and Razzolini L and Riccaboni M and Signoriello E and Agostoni G and Farina A and Mondino M and Berruto F and Tettamanti A and Donnaloja F and Tortorella C},
  year = {2024},
  journal = {Neurology and therapy},
  doi = {10.1007/s40120-024-00644-3},
  url = {https://doi.org/10.1007/s40120-024-00644-3}
}

RIS

TY  - JOUR
TI  - Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project.
AU  - Paolicelli D
AU  - Borriello G
AU  - Clerici R
AU  - Colombo E
AU  - Croce D
AU  - D'Amico E
AU  - De Rossi N
AU  - Di Sapio A
AU  - Fenu G
AU  - Maimone D
AU  - Marfia GA
AU  - Moccia M
AU  - Perini P
AU  - Piscaglia MG
AU  - Razzolini L
AU  - Riccaboni M
AU  - Signoriello E
AU  - Agostoni G
AU  - Farina A
AU  - Mondino M
AU  - Berruto F
AU  - Tettamanti A
AU  - Donnaloja F
AU  - Tortorella C
PY  - 2024
JO  - Neurology and therapy
DO  - 10.1007/s40120-024-00644-3
UR  - https://doi.org/10.1007/s40120-024-00644-3
ER  -

APA

D, P., G, B., R, C., E, C., D, C., E, D., N, D. R., A, D. S., G, F., D, M., GA, M., M, M., P, P., MG, P., L, R., M, R., E, S., G, A., A, F., M, M., F, B., A, T., F, D., & C, T. (2024). Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project.. Neurology and therapy. https://doi.org/10.1007/s40120-024-00644-3

Source records

pubmed · retrieved 2026-09-25T07:38:06.309Z